The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
A tongue-in-cheek guide for passengers affected by the electronic hand luggage ban, by a Middle Eastern airline.
Police are treating the death as suspicious and a post-mortem examination is due to be carried out.
The footage was only discovered by June Jones' family when her son Darren stumbled across it whilst browsing Facebook.